

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07K 14/47, 14/705, C12N 15/12, 5/10, C12Q 1/68, G01N 33/53, C07K 19/00, A61K 38/16, C07K 16/18	A2	(11) International Publication Number: WO 96/26958 (43) International Publication Date: 6 September 1996 (06.09.96)
(21) International Application Number: PCT/US96/02673 (22) International Filing Date: 23 February 1996 (23.02.96) (30) Priority Data: 08/395,415 27 February 1995 (27.02.95) US (71) Applicant: PRESIDENT AND FELLOWS OF HARVARD COLLEGE [US/US]; 17 Quincy Street, Cambridge, MA 02138 (US). (72) Inventors: FLANAGAN, John, G.; 20 Glen Road, Newton, MA 02159 (US). BERGEMANN, Andrew, D.; 108 Gains- borough Street, Boston, MA 02115 (US). (74) Agents: GRANAHAH, Patricia et al.; Hamilton, Brook, Smith & Reynolds, Two Militia Drive, Lexington, MA 02173 (US).		(81) Designated States: European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>Without international search report and to be republished</i> <i>upon receipt of that report.</i>
(54) Title: Eph RECEPTOR LIGAND ELF-2 (57) Abstract <p>This invention encompasses an isolated DNA encoding all or a portion thereof of a novel member, ELF-2, of a family of ligands of the Eph receptor tyrosine kinases, along with the isolated polypeptides expressed by the DNA. The invention further encompasses DNA encoding forms of the ELF-2 ligand and polypeptides corresponding thereto. The ELF-2 ligand is important in cellular communication during pattern formation in embryos and can be used to alter neurological development, oncogenesis, and growth regulation.</p>		